Intrexon Corporation, a next generation synthetic biology company, today announced an agreement with Novici Biotech LLC in which Intrexon has licensed certain non-exclusive rights to the use of Novici’s patented GRAMMR technology for high-resolution genetic reassortment (“gene shuffling”).
According to Grace Colón, PhD, President of Intrexon’s Industrial Products Division, Intrexon will be deploying Novici’s GRAMMR technology toward a spectrum of industrial applications in concert with Intrexon’s UltraVector® platform and extensive library of modular DNA control components. “Gene shuffling has been one of the cornerstone genetic technologies for optimization of industrial biomolecules,” states Colón. “The coordinated deployment of Novici’s GRAMMR technology with our core UltraVector platform enables Intrexon to amplify the power of gene shuffling by incorporating optimized genes into our integrated genetic circuits and cellular control frameworks. The two platforms are an excellent complement and we look forward to maximizing the apparent synergies to derive high value industrial products.”
“We are very pleased that Intrexon has chosen GRAMMR as a key upstream technology for use in its industrial products development,” states Hal Padgett, PhD, Novici’s General Manager and Chief Science Officer. “Intrexon’s industrialization of complex transgene assembly, coupled with a superior ability to control cellular machinery, should produce many novel industrial applications and substantial improvements to existing ones. We look forward to enabling their use of GRAMMR and expect a very productive relationship.”
The GRAMMR licensing agreement is part of Intrexon’s ongoing strategic deployment of top-tier third party technologies in combination with the company’s industry-shaping synthetic biology capabilities. Terms of the agreement were not made public.
About Intrexon Corporation
Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products and agricultural biotechnology. The company’s advanced transgene engineering platform enables Better DNA™ by combining breakthroughs in DNA control systems with corresponding advancements in modular transgene design, assembly and optimization. The company is currently using these advanced capabilities to undertake foremost challenges across the spectrum for biological applications. More information about the company is available at www.DNA.com.
About Novici Biotech (www.novicibiotech.com)
Novici Biotech LLC is a private biotechnology company offering proprietary synthetic biology tools and directed evolution capabilities to advance the product-focused goals of our clients in the pharmaceutical, agricultural, and industrial fields. Novici’s patented GRAMMR technology for high-resolution genetic reassortment is at the heart of our ability to enhance gene functionality at both the nucleotide and protein level. Novici is focused on bringing to market these unique synthetic biology technologies, including the means to empirically optimize the codon usage structure of any gene to endow it with optimal expression yield, protein folding integrity, and cell type compatibility, and to optimize protein structure and function for commercial use. For more information, please visit our website: www.novicibiotech.com.